Health & Fitness

HIV vaccine trailed in South Africa


As HIV continues to wipe out generations in Africa and more so poses as a lasting challenge in Uganda, a vaccine against HIV will be trialed in South Africa later this year after meeting the criteria needed to prove it could help fight the epidemic in Africa.

A small trial, known as HVTN100, took place in South Africa in 2015 to test the safety and strength of immunity the vaccine could provide, ahead of any larger-scale testing in affected population.

Two-hundred and fifty-two healthy volunteers were enrolled to receive either the vaccine, known as ALVAC-HIV/gp120, or a placebo to compare the extent of immune response generated. The results were presented at the 21st International AIDS Conference in Durban, South Africa on Tuesday last week.

“This was precautionary to see if the vaccine looks promising,” said Linda Gail Bekker, deputy director of the Desmond Tutu HIV Centre in Cape Town, South Africa, and president-elect of the International AIDS Society, who is leading the vaccine trials.

The vaccine stems from a landmark trial in Thailand in 2009 that was the first to show any protection against HIV, with 31% protection against the virus. This was enough to get experts in the field excited after years with no success.

“The obvious question is: Can we now replicate those results and can we improve upon them with greater breadth, depth and potency?” said Anthony Fauci, Director of the National Institutes of Allergy and Infectious Disease, whose organization sponsors the study.

The vaccine was improved for use in the higher-risk populations of sub-Saharan Africa, where a different subtype of the virus also exists.

“We’ve inserted specific inserts from viruses that have come off the subcontinent,” said Gail Bekker. A new component was also introduced to stimulate stronger immunity, known as an adjuvant.

Four criteria were set as measures of its likely effectiveness, including the level of T-cell and antibody response to fight the virus if it were to infect.

“It gives the tick on all four, it does look promising and it should launch,” Gail Bekker said. “We wanted to see a particular immune picture that would suggest that a big efficacy trial would be likely to yield results,” she said.

“[This] was like the gatekeeper of will we or will we not go ahead,” Fauci said, “and the answer is ‘yes’.”

A larger-scale trial of the vaccine will now begin in 5,400 people across four sites in South Africa in November 2016 and run for three years. A fifth dose of the vaccine will also be given in hope of longer-lasting protection.

The Thai study showed 60% protection against HIV after one year, but this fell to 31% by the end of the trial. The team hopes the new regimen will bring protection levels back up.

Hopefully, there is a possibility for the long standing HIV epidemic challenge to be solved once and for all.

Theinsider Uganda is a news publishing website. We are located at Suite G25 Metroplex Shopping mall, Naalya Kampala Uganda.
Enter ad code here

Copyright © 2016 Theinsider Uganda. Unearthing the truth

To Top